reports
- Daniel Appiah
Expansion to sustain growth with boosted capacity
hVIVO is establishing a new facility in the Canary Wharf life sciences hub, London. This will increase its quarantine bed capacity and provide greater flexibility to meet anticipated higher demand for its human challenge clinical trial services. The new site, which management notes is mostly funded
EQS-News: hVIVO hails growing contract values after winning £13.6mln R...
EQS-News: hVIVO PLC hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal 14.11.2022 / 12:14 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -n...
- Daniel Appiah
Open Orphan: Booming orders show market leadership
Open Orphan (which will be rebranded hVIVO starting 26 October) is a growing specialist contract research organisation (CRO) with a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). It has reported in the H1FY22 results revenues of
- Daniel Appiah
Open Orphan delivering on growth expectations
Open Orphan is a growing specialist contract research organisation (CRO) with a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). High demand for hVIVO's challenge studies in respiratory infections and infectious diseases, helped t
- John Savin PhD
- Robin Davison
Open Orphan: profitable outlook for 2022
In just over two years Open Orphan (Open), a rapidly growing specialist contract research organisation (CRO), has built a high-growth London-based clinical trial business (hVIVO) supported by a European clinical services subsidiary (Venn). High demand for hVIVO's challenge studies in respiratory in
- Emma Ulker
Open Orphan: Sustaining commercial traction
Open Orphan PLC, a specialist pharmaceutical services company, and the world leader in the testing of vaccines and antivirals using human challenge studies, continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities.
- Emma Ulker
Open Orphan: Firm foundations for growth laid in H1
In the six-month period to June 2020, ORPH focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in January. The company is currently positioned to deliver and maximise the potential its world-leading clinical research organisation
- Emma Ulker
Open Orphan: World-leading expertise drives growth
Open Orphan (LON:ORPH) has rapidly restructured and integrated its Venn and hVIVO subsidiaries, and is delivering on its growth strategy by maximising its specialist capabilities and is converting a pipeline with an estimated value of over £100mln, to deliver long-term, profitable contracts. This w
- Emma Ulker
Open Orphan: Focused on a buoyant outlook
Open Orphan (ORPH) is a specialist Contract Research Organisation (CRO) offering pharmaceutical services relating to orphan and emerging therapies, and is pioneer in the testing of vaccines and anti-viral treatments through the use of human viral challenge (HVC) studies. FY19 financial results refl
Hardman & Co Research: Open Orphan presenting at virtual Investor Foru...
Hardman & Co Research Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020 17-Jun-2020 / 09:32 GMT/BST Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020 We are delighted to announce that Open Orphan will be presenting at our next Investor Forum on Thursday 9th July. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A. Open Orphan (ORPH) is a publicly traded company on the London AIM and Euronext Growth sto...
- Emma Ulker
Open Orphan: Scaling Up, Leveraging Valuable Assets
Open Orphan PLC (LON:ORPH) is a specialist contract research organisation (CRO) offering pharmaceutical services focused on orphan drugs. It is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services. With its hVIVO subsidiary now integr
- Emma Ulker
Open Orphan: Leveraging expertise and relationships for growth
Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The sector is reported to be growing at circa 11%, double the growth rate of the broader pharma market. The company’s Venn Life Scie
- Emma Ulker
Open Orphan: creating a valuable niche
Open Orphan (ORPH) presents an opportunity to invest in a companytargeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market, which is growing at around 11% a year, around twice as fast as the global pharmaceuticals market. At the same time, there is a great dis
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.